SO-145 on skin microbiome for atopic dermatitis

Cross-over comparative study of the skin microbiome for atopic dermatitis using soap SO-145

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041220073

Enrollment

Registered

2022-10-14

Start date

2022-10-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis atopic dermatitis

Interventions

After registration, the study subjects will receive skin care guidance and will be washed with soap once a day according to a certain method. Use SO-145 soap containing FSDG and placebo soap for 12 we

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Among patients with mild atopic dermatitis 1. Patients who have received sufficient explanation before participating in this study, and who have obtained written consent at the discretion of the patient or their guardian with sufficient understanding. 2. Staphylococcus epidermidis and Staphylococcus aureus carriers in patients with mild or mild eruption who have been diagnosed with atopic dermatitis based on the definition and diagnostic criteria for atopic dermatitis.

Exclusion criteria

Exclusion criteria: 1. Adrenal steroids Taking steroids, intensifying the platinum immunomodulatory drug 2. Basic sterilization Illness Slightly preventive bactericidal drug is taken internally 3. Patients who are recommended to use topical steroids on the face 4. Patients who originally use FSDG for soap 5. Patients, researchers, research coordinators

Design outcomes

Primary

Measure	Time frame
Percentage of Staphylococcus epidermidis 12 weeks after the start of use	—

Secondary

Measure	Time frame
1. Percentage of Staphylococcus epidermidis 4 and 12 weeks after the start of use and 4 weeks after the end of use 2. Percentage of Staphylococcus aureus 4 and 12weeks after the start of use and 4 weeks after the end of use (Measurement method: Sequence analysis of the bacterial flora on the cheeks of patients who have not used cosmetics for more than 7 hours after washing their face.) 3. Percentage of Staphylococcus aureus, TEWL, keratin water content, pH 4 and 12 weeks after the start of use and 4 weeks after the end of use (Use the TEWL, keratin water content, and pH measurement results of the patient's cheeks 7 hours or more after washing the face and without using cosmetics.) 4.Changes in serum TARC level, milk-specific IgE level and amount of change in activation of effector cells 12 weeks after the start of use 5.Changes in bacterial flora diversity by skin bacterial flora sequence analysis 4 to 12 weeks after the start of use and 4 weeks after the end of use	—

Measure

Time frame

1. Percentage of Staphylococcus epidermidis 4 and 12 weeks after the start of use and 4 weeks after the end of use 2. Percentage of Staphylococcus aureus 4 and 12weeks after the start of use and 4 weeks after the end of use (Measurement method: Sequence analysis of the bacterial flora on the cheeks of patients who have not used cosmetics for more than 7 hours after washing their face.) 3. Percentage of Staphylococcus aureus, TEWL, keratin water content, pH 4 and 12 weeks after the start of use and 4 weeks after the end of use (Use the TEWL, keratin water content, and pH measurement results of the patient's cheeks 7 hours or more after washing the face and without using cosmetics.) 4.Changes in serum TARC level, milk-specific IgE level and amount of change in activation of effector cells 12 weeks after the start of use 5.Changes in bacterial flora diversity by skin bacterial flora sequence analysis 4 to 12 weeks after the start of use and 4 weeks after the end of use

—

Contacts

Public ContactYasuto Kondo

FUJITA HEALTH UNIVERCITY BANTANE HOSPITAL

ykondo@fujita-hu.ac.jp+81-52-321-8171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026